Douglas Adkins

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

Vivek Subbiah, Mimi I. Hu, Lori J. Wirth et al. · The Lancet Diabetes & Endocrinology · 2021 · 353 citations · Full text

Medicine, Endocrinology, Oncology +9

Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study

Mahesh Kudrimoti, Amarintha Curtis, Samar Azawi et al. · Journal of Biotechnology · 2016 · 74 citations · Full text

Pharmacy, Oncology, Pharmacology +15

Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy

Gary Spitzer, Douglas Adkins, Manoj Mathews et al. · Bone Marrow Transplantation · 1997 · 69 citations

Medicine, Hematology, Oncology +17

Outcomes of High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in Stage IIIB Inflammatory Breast Cancer

Douglas Adkins, Robert W. Brown, K. Trinkaus et al. · Journal of Clinical Oncology · 1999 · 43 citations

Medicine, Oncology, Radiation Oncology +17

Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide

Mark D. Girgis, C.L. Hallemeier, William Blum et al. · Blood · 2004 · 38 citations

Medicine, Hematology, Immunology +15